Tag Archives: Europe

Hot Life Science Investor Mandate 3: Global VC Firm Seeking Investments for Multiple Funds

17 Jul

A Venture Capital firm, with offices in the Eastern US and Europe, currently manages three active funds, two focused on private equities and one focused on public equities. The firm is currently in the process of raising a private equity fund that it plans to have its first close in Sept/Oct 2014. The firm’s private equity funds make investments in the form of preferred equity; the public equity fund invests in the form of PIPEs and public market placements. The size of the firm’s investments is highly varied, as the firm pursues a great variety of opportunities with investments falling anywhere in the €2-€15 million range. The firm is actively seeking new investments in the life science sector, and will consider potential opportunities in Europe and North America.

The firm’s new fund plans to invest broadly in the life sciences across sectors of therapeutics, diagnostics, devices and healthcare IT. The fund is very open across stage, indication and technology types with a slight preference for companies working with platform technologies. The firm also manages a fund that focuses on medical devices, diagnostics and healthcare IT companies with products on the market or close to commercialization. With this fund the firm specifically looks for opportunities that are both increasing quality and reducing the cost of care.

The firm places a considerable focus on technology when vetting deals; the partners of the firm are MDs, PhDs or both. In addition to strong technology the firm prefers to invest in management teams with strong track records and deep domain expertise, preferably with prior experience of achieving success in a venture-backed life science company. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: European PE Seeks Early-Stage Companies, Has Long Timeline to Exit

5 Dec

A private equity firm that was founded in 2001 and is based in Europe controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment, and is also interested in the in-licensing of early stage assets. The firm has an 8-year period to exit, and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.

The PE is currently most interested in companies developing Therapeutics and Medical Devices, and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has a preference for companies in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space, the firm has a strong preference for investing in cardiovascular devices, but considers other opportunities as well. The firm looks to invest in very early stages of company development – generally when lead assets are preclinical and technologies are still in development.

This firm looks to make seed investments and in some cases be involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

Hot Life Science Investor Mandate 3: Opportunistic European VC Actively Seeking New Investments

6 Nov

A venture capital firm with several offices worldwide is based primarily in Europe, and co-manages an early-stage fund focused on academic spinouts and seed investments in Europe. The firm has approximately €500M AUM, and is currently managing four active funds. The firm makes equity investments in life science and biomedical technology companies at all stages of development. However, the VC prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €3M to €7M. The firm looks for companies that are based in the US, Canada, and Europe. They are actively screening new investment opportunities.

This group is fairly opportunistic in the life sciences space, but generally targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and has no specific preference in indication. In medical devices, they have a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The VC invests in companies at all stages of their development. For drug development, they invest from late preclinical to mid-stage clinical development. Sometimes they will consider companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

%d bloggers like this: